Dr. Scott Antonia is a recognized leader in the research and clinical application of immunotherapy for the treatment of malignant pleural mesothelioma and lung cancer. He practices at the Duke Cancer Institute (DCI), is a member of the Duke Human Vaccine Institute, and is the Director of the DCI Center for Cancer Immunotherapy, which aims to enhance the institute’s ability to develop and test novel immunotherapeutic approaches. Dr. Antonia is also a professor of Medical Oncology and a part of the DCI Thoracic Oncology disease group.

Dr. Antonia is recognized internationally as a leader in the development of immunotherapy treatments for lung cancer. He directs the Center for Cancer Immunotherapy at Duke Cancer Institute. His research focus is on discovering immunotherapy protocols that show promise in any cancer type. His earlier research and role as global principal investigator led to a shift in the standard of care for stage III non-small-cell lung cancer, establishing anti-PDL1 as consolidative therapy after being combined with chemotherapy and radiation therapy. He was also the lead investigator of clinical trials that established the clinical activity of immunotherapy for small cell lung cancer, resulting in the inclusion of this modality in the National Comprehensive Cancer Network’s treatment guidelines.